GW Pharmaceuticals (NASDAQ: GWPH) reported third-quarter 2020 financial results before the regular trading hours on Tuesday. The company, which specializes in cannabinoid
GW Pharmaceuticals PLC
-(GWPH)
XNAS:GWPH
GW Pharmaceuticals PLC (GWPH) Q2 2020 Earnings Call Transcript
GW Pharmaceuticals PLC (NASDAQ: GWPH) Q2 2020 earnings call dated August 06, 2020 Corporate Participants: Stephen Schultz -- Vice President of Investor Relations Justin
GW Pharmaceuticals (GWPH): Investments in manufacturing and international expansion serve as strong growth drivers
GW Pharmaceuticals plc (NASDAQ: GWPH) has seen its stock gain over 17% in the past one month. The company delivered topline growth
GW Pharmaceuticals PLC (NASDAQ: GWPH) Q1 2020 Earnings Call Transcript
GW Pharmaceuticals PLC (GWPH) Q1 2020 earnings call dated May. 11, 2020 Corporate Participants: Stephen Schultz -- Vice President, Investor Relations Justin Gover -- Chief Executive
Stock Analysis: GW Pharma (GWPH) offers irresistible upside potential
For GW Pharmaceuticals (NASDAQ: GWPH), the main growth strategy for the current fiscal year is to expand its product pipeline beyond Epidiolex,
GW Pharma (GWPH) Q4 loss narrows on strong sales; set to launch Epidiolex in Europe
GW Pharmaceuticals (NASDAQ: GWPH) reported a narrower net loss for the fourth quarter of 2019 as net sales rose sharply, with strong
What to look for when GW Pharmaceuticals (GWPH) reports Q4 earnings
GW Pharmaceuticals plc (NASDAQ: GWPH) is slated to report fourth quarter 2019 earnings results on Tuesday, February 25, after the market closes.
GW Pharmaceuticals (GWPH) posts better-than-expected Q3 results
GW Pharmaceuticals (NASDAQ: GWPH) beat revenue estimates and reported a narrower-than-expected loss for the third quarter of 2019. Despite the beat, the stock tumbled
What to expect from GW Pharmaceuticals’ Q3 2019 earnings report?
GW Pharmaceuticals (NASDAQ: GWPH) is slated to report third quarter 2019 earnings results on Tuesday, November 5, after the market closes. Analysts
Pot giants gain on DEA announcement; GW Pharmaceuticals continues to decline
Marijuana giants received a major boost on Monday after the US Drug Enforcement Administration (DEA) announced that it would initiate steps to
DEEP FOCUS: Everything you need to know about GW Pharmaceuticals
Shares of GW Pharmaceuticals (NASDAQ: GWPH) have gained 72% in the year-to-date period, emerging as a new favorite among pot investors. However,
GW Pharmaceuticals’ stock climbs on Q1 results beat
Medical marijuana company GW Pharmaceuticals (NASDAQ: GWPH) beat market expectations on revenue and earnings for the first quarter of 2019, sending shares
Wall Street expects a revenue surge from GW Pharmaceuticals in Q1
Medical marijuana company GW Pharmaceuticals (NASDAQ: GWPH) is scheduled to report first-quarter 2019 earnings results on May 6, Monday, after the closing
Tilray posts wider-than-expected Q4 loss
Tilray (TLRY) reported a wider loss in the fourth quarter due to higher operating costs and expenses. For surviving the rising competition
Cara Therapeutics stock surges after reporting Q4 earnings results
Cara Therapuetics (CARA) reports a loss of $20.7 million or $0.52 per share on revenue of $5.5 million for the fourth quarter
Earnings Preview Q4: Cara Therapeutics’ success in 2019 will depend on Korsuva trial outcomes
Cara Therapeutics (CARA) is scheduled to report its fourth quarter and full-year 2018 financial results on Tuesday, March 12, after the regular
GW Pharma stock rises after reporting earnings results for the quarter ended Dec. 31, 2018
As GW Pharmaceuticals (GWPH) moved its fiscal year beginning to January 1, 2019, the company reported financial results for the quarter ended 31
Earnings Preview: GW Pharma to widen losses in to-be-reported quarter
GW Pharmaceuticals PLC (GWPH) is expected to post its quarterly earnings on Feb. 26. Last week, GW Pharma saw its stock slide
Despite headwinds sin stocks look solid in 2019
There is no denying the fact that the sin industry – comprising cannabis, tobacco, alcohol and gambling sectors – is relatively undeterred
GW Pharma Q4 results fails to impress the street
GW Pharmaceuticals plc (Nasdaq: GWPH) stock was down about 4% in the extended hours of trading after the company missed analyst estimates
Earnings preview: GW Pharmaceuticals’ cannabis-based drug to play a major role in the future
The UK-based GW Pharmaceuticals (Nasdaq: GWPH) is set to report its fourth quarter and fiscal 2018-end results for the period ending September